The prevalence, risk factors and prognosis of aspirin resistance in elderly male patients with cardiovascular disease

Aging Male

Volumn 15, Issue 3, 2012, Pages 140-147

  Cao, Jian ^a   Liu, Lin ^a   Fan, Li ^a   Chen, Tianmeng ^a   Hu, Guoliang ^a   Hu, Yixin ^a   Zhu, Bingpo ^a   Li, Jian ^a   Wang, Hao ^a   Li, Xiaoli ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Aspirin resistance; Cardiovascular disease; Elderly male patients

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; DUAL SPECIFICITY PHOSPHATASE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN; PROTEIN C; TRIACYLGLYCEROL; URIC ACID;

AGED; ANALYTIC METHOD; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; FOLLOW UP; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; LIGHT TRANSMISSION AGGREGOMETRY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLATELET MAPPING ASSAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DRUG RESISTANCE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 84864837512     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2012.666584     Document Type: Article

References (45)

1. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. Clin Geriatr Med 2009;25:563-577, vii.
2. Zheng Y, Stein R, Kwan T, Yu C, Kwan J, Chen SL, Hu D. Evolving cardiovascular disease prevalence, mortality, risk factors, and the metabolic syndrome in China. Clin Cardiol 2009;32:491-497.
3. National Heart, Lung, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. National Institute of Health. Bethesda, MD;2006.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965.
6. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120:631-635.
7. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: Implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829-1843.
8. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol 2009;103:20A-26A.
9. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008;336:195-198.
10. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-390.
11. Fitzgerald R, Pirmohamed M. Aspirin resistance: Effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011;130:213-225.
12. Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 2003;108:910-911.
13. Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg 2009;50:1500-1510.
14. Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, Papp E, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol 2010;2:171-186.
15. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis 2009;52:141-152.
16. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thromboleastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005;1:1705-1709.
17. Dussaillant NG, Zapata MM, Fardella BP, Conte LG, Cuneo VM. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chil 2005;133:409-417.
18. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
19. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-969.
20. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, et al.; American College of Cardiology American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) American College of Emergency Physicians Society for Cardiovascular Angiography and Interventions Society of Thoracic Surgeons American Association of Cardio vascular and Pulmonary Rehabilitation Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-e304.
21. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: An analysis from the aspirininduced platelet effect (ASPECT) study. Diabetes 2007;56:3014-3019.
22. Lordkipanidz M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
23. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-3164.
24. Carroll RC, Worthington RE, Craft RM, Snider CC, Dakin PA, Wortham DC, Scott J, Jarrett A. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. Thromb Res 2010;125:e118-e122.
25. Ertugrul DT, Tutal E, Yildiz M, Akin O, Yaln AA, Ure OS, Yilmaz H, et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:2897-2901.
26. Pulcinelli FM, Riondino S. More on aspirin resistance: Position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm. J Thromb Haemost 2006;4:485-487.
27. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
28. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
29. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007.
30. Kojuri J, Mahmoody Y, Sabegh BZ, Jannati M, Mahboodi A, Khalili A. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. Cardiovasc Ther 2010;28:147-152.
31. Christiaens L, Ragot S, Mergy J, Allal J, Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: A prospective study. Blood Coagul Fibrinolysis 2008;19:235-239.
32. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:37-42.
33. Eikelboom JW, Hankey GJ, Thom J, Claxton A, Yi Q, Gilmore G, Staton J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomized crossover trial. J Thromb Haemost 2005;3:2649-2655.
34. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and metaanalysis. Arch Intern Med 2007;167:1593-1599.
35. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008;99:14-26.
36. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2008;6:444-450.
37. Chu JW, Wong CK, Chambers J, Wout JV, Herbison P, Tang EW. Aspirin resistance determined from a bed-side test in patients suspected to have acute coronary syndrome portends a worse 6 months outcome. QJM 2010;103:405-412.
38. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
39. Zhang Z, Foster JK, Kolm P, Jurkovitz CT, Parker KM, Murrah NV, Anderson GT, et al. Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: Results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 2006;152:770-776.
40. Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: Results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-79.
41. Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S, Plutecka H, Szczeklik A. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost 2007;98:201-209.
42. Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2009;27:24-28.
43. Santos MT, Fuset MP, Ruano M, Moscard A, Valles J. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009;104: 1618-1623.
44. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-1847.
45. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008;6:46.